证券代码：002603 证券简称：以岭药业 公告编号：2024-007 石家庄以岭药业股份有限公司 关于预计 2024 年度日常关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、 日常关联交易基本情况 （一）日常关联交易概述 石家庄以岭药业股份有限公司（以下简称"公司"或"本公司"）及子公司因经 营需要，与公司控股股东以岭医药科技有限公司（以下简称"以岭医药科技"）及 其子公司以岭络病健康医疗管理有限公司（以下简称"以岭络病"）、河北以岭国 医堂健康医疗管理有限公司（含分公司）（以下简称"以岭国医堂"）、以岭德衡 医院（衡水）有限公司（以下简称"以岭德衡医院"）、石家庄以岭健康体检中心 有限公司（以下简称"以岭体检中心"）、以岭互联网医院（河北）有限公司（以 下简称"以岭互联网医院"）以及河北以岭医院之间存在日常经营性关联交易。 根据公司（含子公司）与关联方 2023 年度交易的实际情况并合理预计，公 司预计 2024 年与关联方日常关联交易总额不超过人民币 6,262 万元。 根据《深圳证券交易所股票上市规则》的规定及《公司章程》等有关规定 ...

石家庄以岭药业股份有限公司董事会 关于独立董事独立性自查情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 等要求，就石家庄以岭药业股份有限公司（以下简称"公司"）第八届董事会在 任独立董事刘骁悍先生、陈刚先生的独立性情况进行评估并出具如下专项意 见： 经核查独立董事刘骁悍先生、陈刚先生的任职经历及其签署的独立性自查 文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股 东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨 碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》及公司《独立董事制度》中对独立董事独立性的相 关要求。 石家庄以岭药业股份有限公司 董事会 2024 年 4 月 27 日 ...

石家庄以岭药业股份有限公司 内部控制评价报告 石家庄以岭药业股份有限公司全体股东： 为加强石家庄以岭药业股份有限公司（以下简称"公司"）的内部控制， 防范和控制公司面临的各种风险，根据财政部、证监会等部门联合发布的《企 业内部控制基本规范》及其配套指引，结合公司内部控制制度和评价办法，在 企业内部控制日常监督和专项监督的基础上，我们对公司 2023 年 12 月 31 日 （内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制、评价 其有效性并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会 建立和实施内部控制进行监督。管理层负责组织领导企业内部控制的日常运行。 公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何 虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性 承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告 及相关信息真实完整，提高经营效率和效果，促进实现公司发展战略。由于内 部控制存在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于 ...

目 录 | 内 容 | 页 次 | | --- | --- | | 一、审计报告 | 1-5 | | 二、已审财务报表 | | | 1.合并资产负债表 | 6-7 | | 2.母公司资产负债表 | 8-9 | | 3.合并利润表 | 10 | | 4.母公司利润表 | 11 | | 5.合并现金流量表 | 12 | | 6.母公司现金流量表 | 13 | | 7.合并所有者权益变动表 | 14-15 | | 8.母公司所有者权益变动表 | 16-17 | | 三、财务报表附注 | 18-113 | 中勤万信会计师事务所 地址：北京西直门外大街 112 号阳光大厦 10 层 电话：（86-10）68360123 传真：（86-10）68360123-3000 邮编：100044 石家庄以岭药业股份有限公司 审计报告 勤信审字【2024】第 1863 号 审 计 报 告 勤信审字【2024】第 1863 号 石家庄以岭药业股份有限公司全体股东： 一、审计意见 我们审计了石家庄以岭药业股份有限公司（以下简称"以岭药业"）财务报 表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并 ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2023, representing a year-on-year increase of 12%[6]. - The net profit attributable to shareholders was RMB 300 million, reflecting a growth of 15% compared to the previous year[6]. - The company's operating revenue for 2023 was ¥10,318,312,851.48, a decrease of 17.67% compared to ¥12,532,841,028.58 in 2022[12]. - Net profit attributable to shareholders for 2023 was ¥1,352,379,242.86, down 42.76% from ¥2,361,804,714.55 in 2022[12]. - The net profit after deducting non-recurring gains and losses was ¥1,264,730,860.67, a decline of 45.58% from ¥2,323,145,344.72 in 2022[12]. - The net cash flow from operating activities was ¥155,457,433.79, a significant drop of 95.54% compared to ¥3,487,736,416.11 in 2022[12]. - Basic earnings per share for 2023 were ¥0.8095, down 42.76% from ¥1.4137 in 2022[12]. - The overall gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[6]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a year-over-year growth of 15%[89]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[89]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[6]. - The company plans to enhance its online sales platform, aiming for a 25% increase in e-commerce sales[89]. - A strategic acquisition of a smaller pharmaceutical company was completed, which is anticipated to enhance the company's product portfolio and increase market share[89]. - The company is expanding its market presence, targeting an increase in distribution channels by 30% in the next year[89]. - The company has established a comprehensive sales network covering over 100,000 medical terminals and 300,000 pharmacies nationwide, enhancing its competitive edge[91]. Research and Development - The company has invested RMB 100 million in R&D for new technologies aimed at enhancing production efficiency[6]. - The company is actively pursuing research and development of new products based on traditional Chinese medicine principles, aiming to address various health issues[54]. - The company has developed a comprehensive drug development technology system guided by the theory of traditional Chinese medicine, positioning it as a leader in the industry[91]. - The company has established a robust R&D framework with various innovation platforms, including a national enterprise technology center and key laboratories for the innovation of traditional Chinese medicine[92]. - The company has completed multiple post-marketing clinical studies for its products, providing a solid evidence base for clinical promotion[91]. - The company has initiated clinical trials for 1 new drug and completed phase III clinical trials for another, indicating progress in its innovative drug development[161]. Product Development and Innovation - New product launches are expected to contribute an additional RMB 200 million in revenue in 2024, driven by innovative drug formulations[6]. - The company has developed 14 patented new drugs, establishing a diverse product portfolio that leads in the treatment of cerebrovascular and respiratory diseases[26]. - The company has received 12 ANDA approvals for the U.S. market, with all products successfully launched, and has submitted registration applications in over 50 countries globally[27]. - The company has developed a comprehensive health product line, including cardiovascular health products, anti-aging immune boosters, fatigue relief, and sleep improvement products[29]. - The company is actively expanding its health industry platform, integrating traditional health concepts with modern technology[29]. Clinical Research and Efficacy - Clinical studies confirm that Tongxinluo capsule significantly reduces the risk of cardiovascular events by 36% and heart-related deaths by 30%[32]. - The randomized, double-blind, international multi-center clinical study on Lianhua Qingwen capsules for treating mild to moderate COVID-19 patients has been successfully completed, demonstrating significant improvement in clinical symptoms and reduced recovery time without adverse reactions[109]. - The study on Tongxinluo capsules for acute myocardial infarction showed a 36% reduction in major adverse cardiovascular events and a 30% reduction in cardiogenic death risk within 30 days, published in JAMA with an impact factor of 120.7[112][113]. - The clinical study on Bazi Bujin capsules for anti-aging has shown significant improvements in kidney deficiency-related symptoms and overall quality of life after 12 weeks of treatment in 530 participants[115]. Regulatory and Compliance - The company has obtained several international patents, including a method for separating eight components in a traditional Chinese medicine composition, valid until 2039[144]. - The company has secured 12 ANDA products approved by the FDA, with 2 additional products under review, and is actively expanding its product pipeline in the U.S. market[124]. - The company has established a comprehensive quality assurance system for its Chinese medicine formula granules, ensuring product safety and effectiveness[118]. Financial Management and Investment - The company achieved a net cash flow from operating activities of ¥155,457,433.79 in 2023, a decrease of 95.54% compared to ¥3,487,736,416.11 in 2022, primarily due to reduced sales receipts[162]. - The total R&D investment for 2023 was ¥934,929,492.52, representing a 4.41% increase from ¥895,472,221.11 in 2022, with R&D expenses accounting for 9.06% of operating revenue, up from 7.15%[161]. - The company plans to invest 30 million CNY in the chemical preparation international industrialization project in 2024 and 2025, with each year's investment expected to be 30 million CNY[172]. Corporate Recognition and Awards - The company was recognized as one of the "Top 100 Chinese Traditional Medicine Enterprises" in 2022, ranking fifth[146]. - The company has received multiple national awards, including one first-class and four second-class National Science and Technology Progress Awards[85].

石家庄以岭药业股份有限公司 2023 年度募集资金存放与使用情况 专项报告 勤信专字【2024】第 0730 号 地址：北京西直门外大街 112 号阳光大厦 10 层 电话：（86-10）68360123 传真：（86-10）68360123-3000 邮编：100044 石家庄以岭药业股份有限公司 2023 年度募集资金存放与使用情况专项报告 勤信专字【2024】第 0730 号 石家庄以岭药业股份有限公司全体股东： 我们接受委托，审核了后附的石家庄以岭药业股份有限公司（以下简称"以 岭药业公司"）董事会编制的《关于 2023 年度募集资金存放与使用情况的专项 报告》（以下简称"募集资金专项报告"）。 一、董事会的责任 以岭药业公司董事会的责任是按照中国证券监督管理委员会发布的《上市 公司监管指引第2号——上市公司募集资金管理和使用的监管要求（2022修订）》 （中国证券监督管理委员会公告〔2022〕15 号）、深圳证券交易所发布的《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》（深证上〔2023〕1145 号）及《深圳证券交易所上市公司自律 监管指南 ...

石家庄以岭药业股份有限公司 2023 年度监事会工作报告 2023 年度，公司监事会严格按照《公司法》《公司章程》和《监事会议事 规则》等法律法规和相关规定，本着恪尽职守、勤勉尽责的工作态度，从切实 维护公司利益和股东的权益出发，认真履行监事会的监督职责。 报告期内，对公司生产经营活动、财务状况、重大事项以及股东大会和董 事会的召开程序，公司董事、高级管理人员的履职情况等方面实施了有效的监 督，较好地保障了公司及全体股东的合法权益，促进了公司的规范运作。现就 本年度的工作情况汇报如下： 一、2023 年度监事会工作情况 报告期内，公司监事会共召开了 7 次会议。具体情况如下： （一）2023 年 2 月 3 日，召开第七届监事会第十七次会议，审议并通过了 《关于使用暂时闲置自有资金购买短期理财产品的议案》。 7、《关于预计 2023 年度日常关联交易的议案》； （二）2023 年 2 月 10 日，召开第七届监事会第十八次会议，审议并通过 了《关于公司监事会换届选举非职工代表监事的议案》。 （三）2023 年 2 月 27 日，召开第八届监事会第一次会议，审议并通过了 《关于选举公司第八届监事会主席的议案》。 ...

证券代码：002603 证券简称：以岭药业 公告编号：2024-006 石家庄以岭药业股份有限公司 关于聘任 2024 年度财务及内控审计机构的公告 成立日期：2013 年 12 月 13 日 组织形式：特殊普通合伙 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、拟聘任会计师事务所事项的情况说明 石家庄以岭药业股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召 开第八届董事会第九次会议，会议审议通过了《关于聘任 2024 年度财务及内控 审计机构的议案》。经公司董事会审计委员会审查，董事会决定聘任中勤万信会 计师事务所（特殊普通合伙）（以下简称"中勤万信"）为公司 2024 年度财务及 内控审计机构，聘期一年，审计费用为 240 万元。 中勤万信具有证券、期货相关业务审计资格，具备为上市公司提供财务审计 及内控审计服务的经验与能力。自 2003 年至 2023 年，中勤万信已连续 21 年为 公司提供财务审计服务，在财务审计工作中，恪尽职守，并能够遵循独立、客观、 公正的职业准则，较好地完成公司财务审计工作。 二、拟聘任会计师事务所的基 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 2,522,632,691.84, a decrease of 35.89% compared to CNY 3,934,956,597.43 in the same period last year[4] - Net profit attributable to shareholders was CNY 303,927,918.74, down 74.73% from CNY 1,202,514,384.13 year-on-year[4] - Basic earnings per share decreased to CNY 0.1819, down 74.73% from CNY 0.7198 in the same quarter last year[4] - Net profit for Q1 2024 was CNY 301,919,698.61, a decline of 74.9% compared to CNY 1,201,436,813.41 in Q1 2023[20] - Total operating revenue for Q1 2024 was CNY 2,522,632,691.84, a decrease of 35.9% compared to CNY 3,934,956,597.43 in the same period last year[19] - Total operating costs decreased to CNY 2,163,331,046.01, down 13.1% from CNY 2,489,342,813.62 year-over-year[19] - The company recorded a total comprehensive income of CNY 301,886,529.06, down from CNY 1,201,780,951.73 in Q1 2023[21] Cash Flow - The net cash flow from operating activities was CNY 117,005,271.96, a decline of 70.77% compared to CNY 400,342,932.75 in the previous year[9] - Cash flow from operating activities generated a net amount of CNY 117,005,271.96, significantly lower than CNY 400,342,932.75 in Q1 2023[22] - The net cash flow from investment activities was 77,304,877.73 CNY, a significant improvement compared to a net outflow of -1,464,282,378.84 CNY in the same period last year[23] - Cash inflow from financing activities totaled 480,526,733.33 CNY, compared to 200,000,000.00 CNY in the previous year, marking a 140.26% increase[23] - The net increase in cash and cash equivalents was 264,337,158.28 CNY, contrasting with a decrease of -870,348,487.30 CNY in the first quarter of the previous year[23] - The ending balance of cash and cash equivalents reached 1,110,971,287.76 CNY, up from 940,314,663.85 CNY year-over-year[23] - The company received 400,000,000.00 CNY in borrowings, an increase from 200,000,000.00 CNY in the same quarter last year[23] - Total cash outflow for financing activities was 410,505,105.19 CNY, compared to 6,231,972.99 CNY in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 17,128,470,785.54, an increase of 0.88% from CNY 16,979,326,536.89 at the end of the previous year[5] - The total liabilities of the company were CNY 4,884,306,169.96, reflecting a decrease from the previous period[16] - The company reported a total liability of CNY 5,388,589,056.51, a decrease from CNY 5,541,331,336.92 in the previous year[20] - The total current liabilities decreased to CNY 4,285,574,207.76 from CNY 4,446,701,155.56, a reduction of about 3.6%[16] - Non-current assets totaled CNY 10,472,109,702.57, slightly up from CNY 10,435,580,799.21, showing a marginal increase[16] - The total equity attributable to shareholders of the parent company rose to CNY 11,753,617,065.70, compared to CNY 11,449,722,316.51 in the previous year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 195,905[11] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., held 31.53% of the shares, totaling 526,775,963 shares[11] Expenses - Research and development expenses increased to CNY 180,592,474.56, up 9.9% from CNY 164,844,076.56 year-over-year[19] - The company reported a significant increase in financial expenses, which rose by 1603.45% to CNY 8,435,692.08 due to decreased interest income[8] Accounting and Auditing - The company did not undergo an audit for the first quarter report[24] - The company has adopted new accounting standards starting from 2024, impacting the financial statements[24]

石家庄以岭药业股份有限公司 注册地址：北京市西城区西直门外大街 112 号十层 1001 董事会审计委员会对会计师事务所 2023 年度履职情况评估及履行监督职责情况的报告 石家庄以岭药业股份有限公司（以下简称"公司"）聘任中勤万信会计师事 务所（特殊普通合伙）（以下简称"中勤万信"）为公司 2023 年度财务及内控审 计机构。根据《中华人民共和国公司法》《中华人民共和国证券法》、《上市公司 治理准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》和《公司章程》、公 司《董事会审计委员会工作细则》的要求，公司审计委员会对中勤万信 2023 年 度履职情况进行评估，董事会审计委员会对中勤万信履行监督职责的情况进行报 告。具体情况如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 1、基本信息： 名称：中勤万信会计师事务所（特殊普通合伙）（以下简称"中勤万信"） 成立日期：2013 年 12 月 13 日 组织形式：特殊普通合伙 首席合伙人：胡柏和 上年度末合伙人数量（2023 年 12 月 31 日）：72 人 ...